Cited by 6,684Acute Ischemic Stroke ManagementIntracerebral and Subarachnoid Hemorrhage ResearchAcute Myocardial Infarction Research

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

Open access
Hacke, Werner, Kaste, Markku, Bluhmki, Erich, Brozman, Miroslav, Dávalos, Antoni, Guidetti, Donata, Larrue, Vincent, Lees, Kennedy R. +6 more·2008·New England Journal of Medicine

Abstract

BACKGROUND: Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. METHODS: After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned patients with acute ischemic stroke in a 1:1 double-blind fashion to receive treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo. The primary end point was disability at 90 days, dichotomized as a favorable outcome (a score of 0 or 1 on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) or an unfavorable outcome (a score of 2 to 6 on the modified Rankin scale). The secondary end point was a global outcome analysis of four neurologic and disability scores combined. Safety end points included death, symptomatic intracranial hemorrhage, and other serious adverse events. RESULTS: We enrolled a total of 821 patients in the study and randomly assigned 418 to the alteplase group and 403 to the placebo group. The median time for the administration of alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alteplase than with placebo (52.4% vs. 45.2%; odds ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.76; P=0.04). In the global analysis, the outcome was also improved with alteplase as compared with placebo (odds ratio, 1.28; 95% CI, 1.00 to 1.65; P<0.05). The incidence of intracranial hemorrhage was higher with alteplase than with placebo (for any intracranial hemorrhage, 27.0% vs. 17.6%; P=0.001; for symptomatic intracranial hemorrhage, 2.4% vs. 0.2%; P=0.008). Mortality did not differ significantly between the alteplase and placebo groups (7.7% and 8.4%, respectively; P=0.68). There was no significant difference in the rate of other serious adverse events. CONCLUSIONS: As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; alteplase was more frequently associated with symptomatic intracranial hemorrhage. (ClinicalTrials.gov number, NCT00153036.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa0804656

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • If the risk of hazard (hemorrhage) is relatively low, then a shift analysis may still be efficient, as reported in ECASS-3.

    “In this example, if the risk of hazard (hemorrhage) is relatively low, then a shift analysis may still be efficient, as reported in ECASS-3 (Figure 1). 39”

    From Statistical Analysis of the Primary Outcome in Acute Stroke Trials (2012) · cites this paper as [39]

    The Efficacy section reports that a post hoc analysis across modified Rankin scale scores favored alteplase (P=0.02), and the safety results report symptomatic intracranial hemorrhage in 2.4% of alteplase recipients. The paper does not test whether a low hemorrhage risk makes shift analysis statistically efficient, so that conditional methodological conclusion is not supported. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [11]11. Albers GW, Olivot JM. Intravenous alte- plase for ischaemic stroke. Lancet 2007; 369:249-50.

Cited by

Sorted by citations

Authors
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., Schneider, D., von Kummer, R., Wahlgren, N., & Toni, D.
Affiliations
  • Heidelberg University (DE)
  • Helsinki University Hospital (FI)
  • Boehringer Ingelheim (Germany) (DE)
  • Hospital Universitari Germans Trias i Pujol (ES)
  • Ospedaliera di Piacenza (IT)
  • Université de Toulouse (FR)
  • University of Glasgow (GB)
  • Boehringer Ingelheim (France) (FR)
  • Leipzig University (DE)
  • Karolinska Institutet (SE)
  • Sapienza University of Rome (IT)
Venue
New England Journal of Medicine
Published
2008-09-25
Volume
359
Issue
13
Pages
1317-1329
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2159233098
Cited by
6,684
References
23
Citations by year
2026: 275 · 2025: 324 · 2024: 359 · 2023: 301 · 2022: 380 · 2021: 411 · 2020: 381 · 2019: 342 · 2018: 369 · 2017: 334 · 2016: 362 · 2015: 443 · 2014: 409 · 2013: 484 · 2012: 484
FWCI
252.44
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Institutional Research Information System (University of Udine) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • Sanofi
  • Les Laboratories Pierre Fabre
  • Novo Nordisk
  • H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Epidemiology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Neurology › Intracerebral and Subarachnoid Hemorrhage Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
alteplase, intravenous thrombolysis, acute ischemic stroke, extended time window, modified Rankin Scale, functional disability, symptomatic intracranial hemorrhage, mortality, treatment safety, stroke treatment efficacy
MeSH terms
Acute Disease, Adult, Aged, Brain Ischemia, Double-Blind Method, Drug Administration Schedule, Female, Fibrinolytic Agents, Humans, Infusions, Intravenous, Male, Middle Aged, Tissue Plasminogen Activator, Time Factors, Logistic Models, Odds Ratio, Treatment Outcome, Intracranial Hemorrhages, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review